A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Phase 1 Completed 39 enrolled Bristol-Myers Squibb

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer

Timeline

Start: 2006-08
Primary completion: 2009-11
Completion: 2009-11

Publications

George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. J Natl Compr Canc Netw. 2011 Sep 1;9(9):1011-8. doi: 10.6004/jnccn.2011.0085.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	1 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	10 mg/kg	Intravenous

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Summary

Timeline

Publications

Drugs

Indications